TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Optical Coherence Tomography to Improve Outcome for Coronary Revascularisation Using Bioresorbable Vascular Scaffolds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥18 years.~2. Patient provides signed written informed consent before any study-specific procedure.~3. De novo native coronary artery disease with lesions that have a distal and proximal reference vessel diameter in the range between 2.25mm and 3.8mm.~4. Single or multi vessel disease. For multi vessel disease up to two vessels and three lesions treated at baseline with no more than two lesions per vessel. Vessel is defined as, left anterior descending, left circumflex, and right coronary arteries. Any branch within the vessel is considered part of the vessel.~5. Full revascularization of all lesions should be achievable (staged PCI not recommended)~6. Elective or ad hoc PCI, stable angina and acute coronary syndrome (NSTE-ACS and STEMI).~7. Angiographically significant (\>50% visual estimation) stenosis present in at least one native coronary artery and evidence of ischemia.~Exclusion Criteria:~1. Subjects with left main lesion.~2. Aorto-ostial lesion location within 3 mm of the aorta junction (both right and left).~3. Subjects with restenosis or stent thrombosis in the target vessel.~4. Severely calcified lesions requiring rotablation.~5. Bifurcation with sidebranch \>2.5mm or any sidebranch that possibly requires treatment with angulation \>70°~6. Severe angulation (\>90°) or excessive tortuosity (\>two 45° angles)~7. Known renal insufficiency (serum creatinine clearance \<45ml/min or receiving dialysis).~8. Vessel(s) and lesion(s) not amenable for PCI, for example diffuse disease.~9. Female of childbearing potential (age \<50 years and last menstruation within the last 12 months), who did not undergo tubal ligation, ovariectomy or hysterectomy~10. Life expectancy less than 1 year.~11. Indication for oral anticoagulation~12. Known allergy against protocol-required medications including ASA, prasugrel, ticagrelor, clopidogrel, heparin, iodinated contrast (the latter in case it cannot be adequately premedicated)~13. History of bleeding diathesis or known coagulopathy.~14. Planned surgery within the next 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- OCT-guided PCI (Type: ACTIVE_COMPARATOR): OCT before and after Stent implantation
- Angiography-guided PCI (Type: ACTIVE_COMPARATOR): OCT after Stent implantation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Educational Intervention to Increase the Emotional Competence of Patients With Oesogastric and Bronchopulmonary Cancers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18 ans,~* Oesogastric or bronchopulmonary cancer patients between 6 months and 2 years after the end of cancer treatments~* Patient of the CHRU (Regional Teaching Hospital) of Lille,~* Registered with a social security scheme~* Speak and understand French language~* Signature of the informed consent to participate in the study.~Exclusion Criteria:~* Cognitive disorders or unstabilized psychiatric disorders that may impair the ability of reasoning and thinking necessary to complete the questionnaires and attend workshops~* Difficulty or deficiency that prevent the patient from a good understanding of the imperatives of the research~* Any situation likely to significantly affect emotional competence during the study according to the investigator's judgment (in particular, ongoing psychotherapy )~* Patients under judicial protection (guardianship or curators).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Emotional skills (Type: EXPERIMENTAL): 3 group sessions where patients are going to learn how to identify, express and regulate their emotions
- Relaxation and talking group (Type: SHAM_COMPARATOR): 3 group sessions where patients are going to follow relaxation instructions and after a non directive talking group about cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Aripiprazole Treatment of the Prodrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* You are between the ages of 13 and 22.~* You are English-speaking.~* You have a diagnosed psychotic disorder, including: schizophrenia, schizophreniform disorder, schizoaffective disorder, or other psychotic disorder~* OR -~* You are experiencing one or more pre-psychotic symptoms like unusual thoughts, suspiciousness, or unusual perceptual experiences.~* You meet additional RAP criteria assessed during screening and interview.~Exclusion Criteria:~* You have a diagnosis of bipolar disorder or major depression with psychotic features.~* You have a history of neurological, neuroendocrine, or other medical conditions known to affect the brain.~* You have past or current substance dependence.~* You are currently taking Aripiprazole.~* You have taken Aripiprazole in the past.~* You are currently taking and responding well to another medication.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 22 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The subject was randomized into Study M10-855 and completed through Week 26 in that study.~* The subject is receiving one or more antipsychotic medications.~Exclusion Criteria:~* Additional history collected during participation in Study M10-855 provides evidence that, in the investigator's judgement, the subject does not have schizophrenia.~* The subject experienced an adverse event or abnormal finding during physical examination, vital signs, laboratory profile, and/or electrocardiogram (ECG) measurements in Study M10-855 that indicates the subject is likely to become medically unstable during the current study.~* The subject is currently taking or is expected to be prescribed any excluded medication without the approval of AbbVie medical monitor.~* The subject is currently enrolled in, or plans to participate in, another interventional study during the course of this trial.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 66 Years
- Healthy Volunteers: f

Study Arms:
- ABT-126 low dose (Type: EXPERIMENTAL): ABT-126 low dose
- ABT-126 middle dose (Type: EXPERIMENTAL): ABT-126 middle dose
- ABT-126 high dose (Type: EXPERIMENTAL): ABT-126 high dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Patient Satisfaction in Palliative Cancer When They Return Home After Hospitalization in Palliative Care

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient (s) age (s) of 18 or more;~* Patient (s) reached (s) from cancer wholly palliative phase (estimated life expectancy of less than 3 months) in the judgment of the investigator;~* Patient (s) hospital (s) in palliative care and candidate for a return home;~* Patient (s) able to communicate with the investigator or his representative;~* Patient (s) have received clear information on the diagnosis and prognosis of their disease;~* Free and informed consent signed.~Exclusion Criteria:~* Patient (s) under guardianship or unable to give informed consent;~* Patient (s) whose cognitive functions can not be questioned.~* Patient (s) whose psychological distress does not participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Medical telephonecontact (Type: EXPERIMENTAL): Evaluations will be conducted by telephone 15 days after hospital discharge, 30 days and then every month until 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Medihoney and Santyl for Burn Injuries

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* New patient presenting with a partial thickness burn injury in at least two non-contiguous locations of the body.~* Enrollment will occur within 72 hours of sustaining a burn injury.~Exclusion Criteria:~* Cognitive or language barriers that preclude completion of study measures.~* Have burn injuries exceeding 40% total body surface area (TBSA).~* Have a diagnosis of immunodeficiency or kidney disease.~* Are receiving treatment (e.g., chemotherapy, dialysis) that can create concerns with immunodeficiency or affect healing.~* Are pregnant.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Medihoney & Santyl (Type: OTHER): Each patient will receive both interventions simultaneously, but on non-contiguous parts of the body that each consist of partial thickness burn injuries of similar depth. For example, if a patient presents with bilateral second-degree burns to the lower extremities, one leg will be treated with MEDIHONEY® GEL with Active leptospermum honey dressing, while the other leg will be treated with SANTYL® ointment dressing. MEDIHONEY® is the target treatment for this study, while SANTYL® is standard care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The PPCGMS Intervention After GDM Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of gestational diabetes during recent pregnancy (4-24 weeks)~* age 18 or older.~* written informed consent~Exclusion Criteria:~* pregestational diabetes (type 1 or type 2)~* include known known skin adhesive allergy which would prevent subject from wearing a CGM,~* history of bariatric surgery or other surgeries that induce malabsorption~* long-term use (\>2 weeks) of systemic steroids during the testing interval~* inability or refusal to comply with protocol

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Blinded CGM (Type: EXPERIMENTAL): Blinded continuous glucose monitor Dexcom G7

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Vitamin E and Vitamin C and Exercise

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 30 to 50 years of age~* Willing to not change eating habits~* Willing to not change physical activity habits~* Willing to complete the 28 week study~* Able to swallow pills~Exclusion Criteria:~* smoke or use tobacco or nicotine in any form including snuff, pills, and patches~* take any medication that makes you unable to do hard exercise~* have cardiovascular, pulmonary, and/or a metabolic disease such as diabetes~* have uncontrolled high blood pressure~* have alcohol, anabolic steroids, or other substance abuse issues~* consume more than 3 alcoholic drinks/week~* have any joint or muscle injuries that affects your ability to exercise~* have cancer (other than skin cancer or carcinoma in situ of the cervix)~* are pregnant or nursing

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Vitamin E and Vitamin C (Type: ACTIVE_COMPARATOR): 4 weeks with Vitamin E and Vitamin C supplementation with no exercise and 4 weeks of supplementation with prescribed exercise.
- Placebo (Type: NO_INTERVENTION): Placebos instead of the Vitamin E and Vitamin C supplements

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mild Therapeutic Hypothermia for Patients With Acute Coronary Syndrome and Cardiac Arrest Treated With PCI

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Survivor of OHCA~* Sustained return of spontaneous circulation (ROSC) for more than 20 minutes after resuscitation~* Unconsciousness with a score of ≤8 on the Glasgow Coma Scale after ROSC~* Shockable initial rhythm~* Diagnosis or suspicion of ACS~Exclusion Criteria:~* Unwitnessed OHCA~* Obvious or suspected pregnancy~* Known serious infection/sepsis before OHCA~* Known bleeding diathesis~* Confirmed or suspected internal bleeding~* Confirmed or suspected acute stroke~* Confirmed or suspected cerebral injury~* Known serious neurological dysfunction (CPC≤4) before OHCA~* Known serious disease making 180 days of survival unlikely~* Hemodynamic instability with systolic blood pressure \<65 mmHg despite treatment~* Time delay from ROSC to MTH induction \> 240 min.~* Asystole or pulseless electrical activity (PEA) as the initial rhythm~* Initial body temperature \<30°C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mild Therapeutic Hypothermia (Type: EXPERIMENTAL): OHCA survivors with diagnosed or suspected ACS
- no-Mild Therapeutic Hypothermia (Type: NO_INTERVENTION): OHCA survivors with diagnosed or suspected ACS

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Quality of Life in Patients With Rectal Cancer Receiving Total Mesorectal Excision With or Without Stoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age older than 18,~* low anterior resection and TME due to rectum carcinoma after standardized neoadjuvant combined chemo- and radiotherapy and receiving adjuvant postoperative chemotherapy,~* German speaking patient who is capable to fill in the questionnaire,~* signed informed consent~Exclusion Criteria:~* age younger than 18,~* preoperative stoma,~* not German speaking~* inability to fill in the questionnaire,~* no standardized chemo- and radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- With protective stoma (Type: None): Patients in which intraoperatively the decision was made to add a protective stoma (following a risk algorithm) to total mesorectal excision. In patients quality of life, the Gastrointestinal Quality of Life Index (GIQLI) questionnaire, Quality of Life Questionnaire for gastrointestinal tract and Faecal Incontinence Score will be applied.
- No stoma (Type: None): Patients in which intraoperatively the decision was made to refrain from adding a protective stoma (following a risk algorithm) to total mesorectal excision.~In patients quality of life, the GIQLI questionnaire (Gastrointestinal Quality of Life Index), Quality of Life Questionnaire for gastrointestinal tract and Faecal Incontinence Score will be applied.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV infected~* \< 200 CD4+ cells/mL~* Active pulmonary tuberculosis (with or without extrapulmonary involvement)~Exclusion Criteria:~* Meningeal tuberculosis~* Unable to attend 96 wk follow-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Receives both, simultaneously antiretroviral therapy and antituberculosis therapy
- Group 2 (Type: EXPERIMENTAL): Receives only antituberculosis therapy, and 2 months afterwards antiretroviral therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective Randomized Study of Medial Patellofemoral Ligament (MPFL) Reconstruction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic patellar instability (more than 2 dislocations)~* Minimum 6 months nonoperative treatment~Exclusion Criteria:~* Severe PF OA~* Acute patellar dislocation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Medial patellofemoral ligament reconstruction
- 2 (Type: ACTIVE_COMPARATOR): Medial reefing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Accuvein in Adult Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adults requiring a venous blood sampling or the placement of a venous peripheral catheter~Exclusion Criteria:~* none

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Venous blood sampling (Type: EXPERIMENTAL): To use Accuvein to improve the effectiveness of venous blood sampling
- Peripheral IV catheter placement (Type: EXPERIMENTAL): To use Accuvein to improve the effectiveness of placing peripheral IV catheter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Trial of IV Lacosamide Versus Phenytoin for Seizure Management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Traumatic Brain Injury (TBI) or Subarachnoid hemorrhage (SAH)~* Admitted to the hospital less than 48 hours prior to randomization~* Glasgow Coma Scale (GCS) score 3-8 (inclusive), or GCS motor score of five or less and abnormal CT scan showing intracranial pathology~* Hemodynamically stable~* Older than 18 years of age~Exclusion Criteria:~* No IV access~* Spinal cord injury~* History of or CT confirmation of previous brain injury, including brain tumor, stroke, or a spontaneous intracerebral hemorrhage~* Hemodynamically unstable~* Suspected anoxia~* Liver failure~* Younger than 18 years of age~* Pregnant~* Allergy to phenytoin or lacosamide~* Inability to obtain consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lacosamide (Type: EXPERIMENTAL): The lacosamide group will receive a loading dose of 400 mg IV, and on maintenance dose of up to 400 mg every 12 hours.
- phenytoin (Type: ACTIVE_COMPARATOR): the phenytoin group will receive a loading dose of 20 mg/K IV, maximum of 2000 mg, given over 60 min. and will be started on a maintenance dose of 5 mg/K/day. Levels will be checked accordingly.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of UVA1-irradiation in the Treatment of Early Skin Fibrosis in Patients Suffering From Systemic Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* systemic sclerosis ACR criteria~* skin fibrosis at least involving the distal third of the lower arm~Exclusion Criteria:~* photosensitizing drugs~* recent UV therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A UVA1 B no UVA1 (Type: OTHER): half body irradiation with random allocation right and left; after three months of treatment treatment of both sides
- A UVA1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues